Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Tango Therapeutics ( (TNGX) ) is now available.
Tango Therapeutics has updated its corporate presentation, highlighting potential breakthroughs in its product pipeline, including best-in-class oral PRMT5 inhibitors and first-in-class oral CoREST inhibitors. These advancements are part of Tango’s strategy to treat a wide range of cancers, with ongoing and planned clinical trials that might significantly impact its market positioning and potential success in cancer therapeutics.
More about Tango Therapeutics
Tango Therapeutics operates within the biotechnology industry, focusing on developing targeted therapies for cancer treatment. The company is engaged in the research and development of novel drugs, including PRMT5 inhibitors and CoREST inhibitors, with a primary market focus on treating multiple common cancers through both standalone and combination therapies.
YTD Price Performance: -6.55%
Average Trading Volume: 1,992,788
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $314.2M
See more data about TNGX stock on TipRanks’ Stock Analysis page.